FrancophonIA/ELRC3.0 huggingface dataset:
English: In particular, tell your doctor or pharmacist if you are taking any of the following: - leflunomide, methotrexate and other medicines that affect the immune system (often called immunosuppressants or immunomodulators) - rifampicin (a medicine used to treat tuberculosis and other infections) - carbamazepine, phenobarbital, phenytoin for epilepsy - St John's wort (a herbal medicine for depression) - repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes - daunorubicin, doxorubicin, paclitaxel, or topotecan for cancer - duloxetine for depression, urinary incontinenece or in kidney disease in diabetics - alosetron for the management of severe diarrhea - theophylline for asthma - tizanidine, a muscle relaxant - warfarin, an anticoagulant used to make the blood thinner (i.e. more fluid) in order to avoid blood clots - oral contraceptives (containing ethinylestradiol and levonorgestrel)
Icelandic: * repagliníð, píóglítazón, nateglíníð eða rósíglítazón við sykursýki * daunorubicín, doxorubicín, paklitaxel eða topotecan við krabbameini * duloxetín við þunglyndi, þvagleka eða við nýrnasjúkdómi vegna sykursýki * alósetrón til meðferðar á slæmum niðurgangi * teófyllín við astma * tizanidín, vöðvaslakandi lyf * warfarín, svokallað segavarnarlyf sem notað er til að þynna blóðið (þ.e. gera það meira fljótandi) til að koma í veg fyrir að blóðkekkir myndist
English: Based on individual prediction of pharmacokinetic parameters using the PopPK model of teriflunomide in healthy volunteers and MS patients, median t1/2z was approximately 19 days after repeated doses of 14 mg. After a single intravenous administration, the total body clearance of teriflunomide is 30.5 ml/h.
Icelandic: Á grundvelli einstaklingsbundinnar spár um lyfjahvarfagildi þar sem PopPK módelið fyrir teriflúnómíð í heilbrigðum sjálfboðaliðum og MS-sjúklingum var notað, var miðgildi t1/2z u.þ.b.
English: In the event of relevant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination.
Icelandic: Verði eitrun eða ofskömmtun, er mælt með gjöf kólestýramíns eða lyfjakola til þess að hraða brotthvarfi.
English: Uncommon (may affect up to 1 in 100 people) - Decrease in the number of blood platelets (mild thrombocytopenia) - Increased feeling or sensitivity, especially in the skin; stabbing or throbbing pain along one or more nerves, problems in the nerves of the arms or legs (peripheral neuropathy) - Nail disorders - Post-traumatic pain
Icelandic: - Fækkun blóðflagna (væg blóðflagnafæð) - Aukin tilfinning eða viðkvæmni, einkum í húð; stingandi verkur eða verkur með slætti í einni eða fleiri taugum, kvillar í taugum í hand- eða fótleggjum (útlægur taugakvilli)
English: - Feeling your heartbeat - Increase in blood pressure - Being sick (vomiting), toothache, upper abdominal pain - Rash, acne - Pain of the tendons, joints, bones, muscle pain (musculoskeletal pain), - Needing to urinate more often than usual - Heavy periods - Pain - Lack of energy or feeling weak (asthenia) - Weight loss
Icelandic: - Verkur í sinum, liðamótum, beinum, vöðvaverkur (verkur í stoðkerfi og stoðvef) - Þörf fyrir að hafa þvaglát oftar en venjulega
English: Pancreatitis, Stomatitis
Icelandic: Stoðkerfi og stoðvefur
English: Route/method of administration
Icelandic: Íkomuleið/aðferð við lyfjagjöf
English: ILD and worsening of pre-existing ILD have been reported during treatment with leflunomide, the parent compound of teriflunomide.
Icelandic: Tilkynnt hefur verið um millivefslungnasjúkdóm og versnun á millivefslungnasjúkdómi sem fyrir er, við meðferð með leflúnómíði sem er móðurefni teriflúnómíðs.
English: Hypertensionb
Icelandic: Taugakerfi
English: Dyslipidaem ia
Icelandic: VIÐAUKI II
English: Hazard ratio (CI95%) 6-month Sustained Disability Progression week
Icelandic: Áhættuhlutfall (CI95%) Hlutfall 6 mánaða viðvarandi aukninaru fötlunar við vika 108
English: - cefaclor, benzylpenicillin (penicillin G), ciprofloxacin for infections - indometacin, ketoprofen for pain or inflammation - furosemide for heart disease - cimetidine for reducing gastric acid - zidovudine for HIV infection - rosuvastatin, simvastatin, atorvastatin, pravastatin for hypercholesterolemia (high cholesterol) - sulfasalazine for inflammatory bowel disease or rheumatoid arthritis - cholestyramine for high cholesterol or relief from itching in liver disease - activated charcoal to reduce absorption of medicines or other substances
Icelandic: * getnaðarvarnir til inntöku (etinýlestradíól og levónorgestrel) * cefaclor, benzylpenisillín (penisillín G), cíprófloxacín við sýkingum * indómetacín, ketóprófen við verkjum eða bólgu
English: Pollakiuria
Icelandic: Naglaraskanir
English: In placebo-controlled studies, peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), was reported more frequently in patients taking teriflunomide than in patients taking placebo.
Icelandic: Í samanburðarrannsóknum með lyfleysu var tíðni úttaugakvilla, þ.m.t. bæði fjöltaugakvilli og eintaugarkvilli (t.d. heilkenni úlnliðsganga) hærri hjá sjúklingum sem fengu teriflúnómíð en hjá þeim sem fengu lyfleysu.
English: cysts and polyps) There does not appear to be an increased risk of malignancy with teriflunomide in the clinical trial experience.
Icelandic: Miðað við reynslu í klínískum rannsóknum virðist ekki vera aukin hætta á illkynja sjúkdómum.
English: Interstitial lung disease
Icelandic: Bráð lifrarbólga
English: Hepatic effects During placebo-controlled studies the following was detected:
Icelandic: Meðan á samanburðarrannsóknum með lyfleysu stóð kom eftirfarandi fram:
English: • alternatively, 50 g of activated powdered charcoal is administered every 12 hours for a period of 11
Icelandic: Annar kostur er að gefa 50g lyfjakol, duft til inntöku á 12 klst. fresti í 11 daga.
English: The risk of male-mediated embryo-fetal toxicity through teriflunomide treatment is considered low.
Icelandic: Hættan á að að eiturverkanir á fóstur geti borist frá karli til konu meðan á meðferð með teriflúnómíði stendur er talin lítil.
English: Musculoskeletal pain,
Icelandic: Truflun á blóðfitu
English: Cholestyramine or activated charcoal
Icelandic: Kólestýramín eða lyfjakol
English: Median time to reach maximum plasma concentrations occurs between 1 to 4 hours post-dose following repeated oral administration of teriflunomide, with high bioavailability (approximately 100%).
Icelandic: eftir lyfjagjöf eftir endurtekna inntöku teriflúnómíðs, með miklu aðgengi (u.þ.b. 100%).
English: • Potential risk of teratogenicity o To check pregnancy status before starting treatment o To educate female patients of child-bearing potential on the need for effective contraception before starting, and during treatment with teriflunomide o To inform their doctor immediately if they stop contraception, or prior to changing contraceptive measures o If female patients become pregnant despite using contraceptive measures, they should stop teriflunomide and contact their doctor immediately who should: Consider and discuss with the patient the accelerated elimination procedure encourage them to enrol in a pregnancy registry (in countries where a pregnancy registry is on-going),
Icelandic: Hætta á vansköpun o Athuga skal mögulega þungun áður en meðferð hefst o Fræða skal konur á barneignaraldri um nauðsyn þess að nota örugga getnaðarvörn áður en meðferð með teriflúnómíði hefst og meðan á henni stendur o
English: A mean decrease affecting white blood cell (WBC) count (<15% from baseline levels, mainly neutrophil and lymphocytes decrease) was observed in placebo-controlled trials with AUBAGIO, although a greater decrease was observed in some patients.
Icelandic: Meðalækkun kom fram sem hafði áhrif á fjölda hvítfrumna (<15% frá grunnlínu, aðallega daufkyrningar og eitilfrumur) í rannsóknum
English: Gender, Elderly, Paediatric patients
Icelandic: Kyn, aldraðir, börn
English: Severe skin reactionsa, Psoriasis (including pustular)b
Icelandic: sóri (graftarbólusóri þ.m.t)b
English: What you need to know before you take AUBAGIO Do not take AUBAGIO:
Icelandic: Ekki má nota AUBAGIO:
English: UAB „SANOFI-AVENTIS LIETUVA“ Tel: +370 5 2755224
Icelandic: Tel: +370 5 2755224
English: Hepatic impairment
Icelandic: - Miklar tíðablæðingar
English: Therefore no dose adjustment is anticipated in mild and moderate hepatic-impaired patients.
Icelandic: Því er ekki gert ráð fyrir skammtaaðlögun hjá sjúklingum með væga og miðlungsmikla skerðingu á lifrarstarfsemi.
English: If a patient taking AUBAGIO develops a confirmed peripheral neuropathy, consider discontinuing AUBAGIO therapy and performing the accelerated elimination procedure.
Icelandic: Íhuga skal að hætta meðferð með AUBAGIO og veita meðferð til að hraða brotthvarfi, ef úttaugakvilli er er staðfestur hjá sjúklingi sem notar AUBAGIO.
English: Influenza, Upper respiratory tract infection, Urinary tract infection, Bronchitis, Sinusitis, Pharyngitis, Cystitis, Gastroenteritis viral,
Icelandic: * zidóvúdín við eyðni * rosuvastatín, simvastatín, atorvastatín, pravastatín við kólesterólhækkun.
English: Accelerated elimination procedure
Icelandic: Aðferðir til að hraða brotthvarfi
English: Not measured
Icelandic: Ekki mælt
English: Fri
Icelandic: Þróttleysi
English: Talk to your doctor or pharmacist before taking AUBAGIO if: - you have liver problems and/or if you drink large amounts of alcohol.
Icelandic: - þú ert með lifrarsjúkdóm og/eða ef þú drekkur verulegt magn af alkóhóli.
English: Effects on immune cell numbers in the blood: In the placebo-controlled studies, teriflunomide 14 mg once a day led to a mild mean reduction in lymphocyte count, of less than 0.3 x 109/l, which occurred over the first 3 months of treatment and levels were maintained until the end of the treatment.
Icelandic: Í samanburðarrannsóknunum með lyfleysu olli teriflúnómíð 14 mg einu sinni á sólarhring vægri meðallækkun á fjölda eitilfrumna, sem nam innan við 0,3 x 10
English: BATCH NUMBER
Icelandic: QT bils
English: Teriflunomide is contraindicated in pregnancy (see section 4.3).
Icelandic: Ekki má nota teriflúnómíð á meðgöngu (sjá kafla 4.3).
English: - severe skin reactions which might include symptoms of skin rash, blistering, or ulcers in your mouth - severe infections or sepsis (a potentially life-threatening type of infection) which might include symptoms of high fever, shaking, chills, reduced urine flow, or confusion - serious liver disease which might include symptoms of yellowing of your skin or the whites of your eyes, darker urine than normal, unexplained nausea and vomiting, or abdominal pain - inflammation of the lungs which might include symptoms of shortness of breath or persistent cough - inflammation of the pancreas which might include symptoms of severe pain in the upper abdominal area that may also be felt in your back, nausea, or vomiting
Icelandic: • alvarlegur lifrarsjúkdómur sem gæti einkennst af gulnun húðar eða hvítu í augum, dekkra þvagi en venjulega, óútskýrðri ógleði og uppköstum eða kviðverkjum
English: Renal impairment
Icelandic: STAKSKAMMTA ÞYNNUR
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS UNIT-DOSE BLISTER
Icelandic: Bólga í lifur, brisi eða munni/vörum Veruleg húðviðbrögð
English: The volume of distribution is 11 l after a single intravenous (IV) administration.
Icelandic: Rúmmál dreifingar er 11 l eftir staka gjöf í bláæð.
English: Increase in ALT (increase in blood levels of certain hepatic enzymes) shown in tests Hair thinning
Icelandic: Alvarleg ofnæmisviðbrögð (m.a. bráðaofnæmi) Áhrif á lungu (millivefslungnasjúkdómur)
English: Gammaglutamyltransfer ase (GGT) increaseb, Aspartate aminotransferas
Icelandic: Hækkun aspartatamínótransferasa b
English: Teriflunomide is contraindicated in this population (see section 4.3).
Icelandic: Ekki má nota teriflúnómíð hjá þessum sjúklingahópi (sjá kafla 4.3).
English: The warnings are appropriate.
Icelandic: Viðvaranirnar eru viðeigandi.
English: Considering the data submitted, the Committee concluded as follows on issues raised in the notification received from Germany and the Netherlands.
Icelandic: Eftir að hafa skoðað innsend gögn komst nefndin að eftirfarandi niðurstöðu varðandi þau atriði sem vakin var athygli á í tilkynningunni frá Þýskalandi og Hollandi.
English: 1 VICH GL6: Guideline on Environmental Impact Assessment (EIAS) for Veterinary Medicinal Products - Phase I
Icelandic: Guideline on Environmental Impact Assessment (EIAS) for Veterinary Medicinal Products - Phase I
English: The benefit-risk for the products can be considered to be positive.
Icelandic: Telja má að ávinningurinn-áhættan fyrir vörurnar sé jákvæður.
English: For the pour-on product 24 concerned member states (CMS) are involved: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia and Spain.
Icelandic: Austurríki, Belgía, Búlgaría, Danmörk, Eistland, Frakkland, Grikkland, Holland, Ísland, Írland, Ítalía, Kýpur, Lettland, Litháen, Lúxemborg, Pólland, Portúgal, Rúmenía, Slóvakía, Slóvenía, Spánn, Tékkland, Ungverjaland, Þýskaland Hvað varðar blettalyfið taka Belgía, Frakkland, Holland og Þýskaland þátt sem hlutaðeigandi aðildarríki.
English: As the PECgroundwater was below 0.1 µg/l no further assessment for the water compartment was required.
Icelandic: Þar sem PECgrunnvatn var undir 0.1 µg/l var ekki þörf á frekara mati fyrir vatnsdeildina.
English: No additional studies were carried out in order to further refine the risk as guidance in this area is not currently available.
Icelandic: Engar aðrar rannsóknir voru gerðar til þess að skilgreina betur áhættuna þar sem leiðbeiningar á þessu sviði eru ekki til staðar eins og er.
English: Add the following text in the relevant sections of the product information:
Icelandic: Bætið eftirfarandi texta við viðeigandi kafla í upplýsingum um lyfið:
English: In order to address the concerns raised by the referral, the applicant provided an environmental risk assessment (ERA) in accordance with VICH guidelines GL61 and GL382 and in accordance with the CVMP guideline in support of VICH guidelines GL6 and GL38 (EMEA/CVMP/ERA/418282/2005)3.
Icelandic: Til þess að taka á þeim áhyggjum, sem komu fram í málskotinu, sendi umsækjandinn inn umhverfisáhættumat í samræmi við VICH viðmiðunarreglurnar GL61 og GL382 og í samræmi við CVMP viðmiðunarreglurnar til stuðnings VICH viðmiðunarreglum GL6 og GL38 (EMEA/CVMP/ERA/418282/2005)3.
English: Route of administration
Icelandic: Dýrategundir Íkomuleið
English: Scientific justifications were provided for the cases of deviations from guidelines and a number of peer reviewed publications were submitted.
Icelandic: Vísindalegar réttlætingar voru gefnar fyrir frávikum frá viðmiðunarreglunum og voru nokkur ritrýnd rit send inn.
English: Deltamethrin was shown to have a half-life in soil of 72 days based on acceptable published data.
Icelandic: Deltametrín var sýnt hafa 72 daga helmingunartíma í jarðvegi á grundvelli viðunandi birtra gagna.
English: Risk management or mitigation measures
Icelandic: Áhættustjórnun eða mótvægisaðgerðir
English: VICH GL38: Guideline on Environmental Impact Assessment for Veterinary Medicinal Products Phase II (CVMP/VICH/790/03)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004393.pdf 3 CVMP Guideline on environmental impact assessment for veterinary medicinal products in support of the VICH guidelines
Icelandic: Guideline on Environmental Impact Assessment for Veterinary Medicinal Products Phase II (CVMP/VICH/790/03)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004393.pdf 3 CVMP Guideline on environmental impact assessment for veterinary medicinal products in support of the VICH
English: Comparison of the predicted environmental concentration (PEC) value for soil with the PNEC showed that the RQ for the soil compartment was <1 and no further assessment was required.
Icelandic: Samanburður á áætluðu gildi umhverfisstyrks fyrir jarðveg (e. predicted environmental concentration, PEC) með PNEC sýndi að RQ fyrir jarðvegsdeildina var <1 og ekki væri þörf á frekara mati.
English: This referral under Article 33(4) of Directive 2001/82/EC was made due to concerns that the applicant had not satisfactorily demonstrated the environmental safety of Deltanil 10 mg/ml Pour-on Solution for cattle and sheep and Deltanil 100 mg Spot-on Solution for cattle due to lack of pivotal data without which it is not possible to conclude on the environmental safety of the products.
Icelandic: Þetta málskot samkvæmt grein 33(4) í tilskipun 2001/82/EB var gert vegna þess að áhyggjur voru uppi um að umsækjandinn hefði ekki sýnt fram á umhverfisöryggi Deltanil 10 mg/ml áhellingarlausnarinnar fyrir nautgripi og fé og Deltanil 100 mg blettalausnarinnar fyrir nautgripi með fullnægjandi hætti vegna skorts á undirstöðugögnum en án þeirra er ekki hægt að leggja mat á umhverfisöryggi lyfjanna.
English: No degradation rate for deltamethrin in sediment was required in order to complete the ERA, but some information in the published literature suggests that in some sediments degradation occurs with a half-life in soil of about 10 days (Åkerblom et al. 2008)4.
Icelandic: Ekki var krafist niðurbrotshlutfalls deltametríns í seti til þess að ljúka matinu á umhverfisáhættum en sumar upplýsingar í birtum ritum benda til þess að eitthvað niðurbrot í seti eigi sér stað þar sem helmingunartími í jarðvegi sé um 10 dagar (Åkerblom et al. 2008)4.
English: The high soil adsorption coefficient (KOC, expressed as logKOC) of >4.2 suggests that any deltamethrin which enters the aquatic environment will move to the sediment.
Icelandic: Hái jarðvegsaðsogsstuðullinn (KOC, expressed as logKOC) >4.2 gefur til kynna að allt deltametrín, sem fer út í vatnsumhverfið, muni færast í set.
English: The use of the products was not expected to pose a risk for soil, groundwater and surface water.
Icelandic: Ekki er gert ráð fyrir því að notkun lyfjanna skapi jarðvegi, grunnvatni og yfirborðsvatni hættu.
English: A new study was carried out on earthworms according to the recommended OECD guideline and a predicted no effect concentration (PNEC) was derived using the accepted assessment factor (10).
Icelandic: Ný rannsókn fór fram á ánamöðkum í samræmi við ráðlagðar viðmiðunarreglur OECD og fékkst spá um samsöfnun án áhrifa (e. predicted no effect concentration, PNEC) með því að nota samþykkta matsstuðulinn (10).
English: It provided all the information required to be able to make a conclusion on the environmental risk presented by the use of the products.
Icelandic: Það veitti allar nauðsynlegar upplýsingar til ákvarðanatöku um umhverfisáhættur af völdum notkunar lyfjanna.
English: Add, where applicable, “Deltamethrin is toxic to aquatic organisms and honey bees and may accumulate in sediment.”
Icelandic: Bætið við, þar sem við á, „Deltamethrin er eitrað vatnalífverum og hunangsflugum og getur safnast fyrir í seti.
English: Acceptable data on the acute toxicity of deltamethrin to dung fly larvae and adult beetles were provided which indicated that RQ values for dung insects were in the order of 90 - 10 000.
Icelandic: Viðunandi gögn um bráð eiturhrif deltametríns á lirfu mykjuflugna og fullorðnar bjöllur voru látin í té og gáfu þau til kynna að RQ gildin fyrir mykjuskordýr væru á skalanum 90 - 10 000.
English: As a result of this referral it was considered that due to the high adsorption coefficient (KOC) of deltamethrin the following environmental information should also be added to the previously agreed warning sentence in the SPC (section 5 Environmental Properties) and the package leaflet (section 15 Environmental Properties) "...and may accumulate in sediment".
Icelandic: Sem afleiðing þessa málskots var talið að vegna hás aðsogsstuðuls (KOC) deltametríns ætti að bæta eftirfarandi umhverfisupplýsingum við áður samþykkta viðvörunarsetningu í yfirlitinu yfir eiginleika lyfsins (kafli 5 Umhverfiseiginleikar) og á fylgiseðlinum (kafli 15 Umhverfiseiginleikar) „... og getur safnast fyrir í seti“.
English: New acute OECD studies were carried out on aquatic organisms followed by an OECD chronic study with daphnia.
Icelandic: Ný OECD bráðarannsókn var gerð á vatnalífverum í kjölfar langvarandi rannsóknar OECD á halaflóm.
English: GL6 and GL38 (EMEA/CVMP/ERA/418282/2005)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004386.pdf
Icelandic: guidelines GL6 and GL38 (EMEA/CVMP/ERA/418282/2005)http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004386.pdf umsækjandanum.
English: The RQ values for surface water were <1 for all target animal types.
Icelandic: RQ gildin fyrir yfirborðsvatn voru <1 fyrir allar markdýragerðirnar.
English: Published data from a field study using a pour-on deltamethrin product indicated that the effects of deltamethrin can persist for a number of weeks and have the potential to affect dung insect populations in some circumstances.
Icelandic: Birt gögn úr vettvangsrannsókn þar sem notað var deltametrín áhellingarlyf gáfu til kynna að áhrif deltametríns geti varað í fjölda vikna og hafi getu á því að hafa áhrif á mykjuskordýr í sumum tilvikum.
English: List of the names, pharmaceutical forms, strengths of the veterinary medicinal products, animal species, route of administration, applicant in the Member States
Icelandic: Listi yfir nöfn, lyfjaform, styrk dýralyfja, dýrategundir, íkomuleiðir, umsækjanda í aðildarríkjunum
English: As deltamethrin has a n-octanol/water partition coefficient (KOW, expressed as logKOW) of >5.1, its bioaccumulation potential, potential for being considered a persistent, bioaccumulative and toxic (PBT) compound and secondary poisoning were addressed as required by the VICH and CVMP guidelines.
Icelandic: Þar sem deltametrín hefur n-oktanól/vatnsdeilistuðulinn (KOW, gefinn upp sem logKOW) >5,1, var tekið á getu þess til uppsöfnunar í lífverum, þrávirkri getu þess, efnasambandi, sem safnast fyrir í lífverum og er eitrað (e. bioaccumulative and toxic compoun, PBT) og fylgieitrun eins og krafist er viðmiðunarreglum VICH og CVMP.
English: Deltamethrin residues will be introduced into the environment following direct excretion onto pasture.
Icelandic: Deltametrínleifar fara út í umhverfið eftir beinan útskilnað í haga.
English: The reference member state (RMS) is the United Kingdom for both products.
Icelandic: Tilvísunaraðildarríkið er Bretland fyrir bæði lyfin.
English: Potential serious risks were identified during the decentralised procedure by Germany and the Netherlands who considered no acceptable data in the environmental risk assessment has been provided on: n-octanol:water partition coefficient (KOW); soil adsorption coefficient (KOC); soil degradation; bioaccumulation (BCF); toxicity to dung insects, and therefore the environmental risk assessment cannot be finalised.
Icelandic: Þýskaland og Holland staðfestu hugsanlegar alvarlegar áhættur í dreifstýrða ferlinu og var litið svo á að í matinu á umhverfisáhættu hefðu engin ásættanleg gögn verið veitt um: n-oktanól:vatnsdeilistuðulinn (KOW); jarðvegsaðsogstuðulinn (KOC); jarðvegsniðurbrot; uppsöfnun í lífverum; eiturhrif á mykjuskordýr, og því væri ekki hægt að ljúka matinu á umhverfisáhættu.
English: The adsorption/desorption of deltamethrin was determined by the HPLC method which showed that deltamethrin was expected to be non-mobile in soil.
Icelandic: Aðsog/afsog deltametríns var ákvarðað með HPLC aðferðinni sem sýndi að búast mætti við að deltametrín væri ekki hreyfanlegt í jarðvegi.
English: Data from an acceptable study gave a bioconcentration factor of 510 l/kg which is below the value of 2000 l/kg which would indicate a potential to bioaccumulate.
Icelandic: Gögn frá samþykktri rannsókn gáfu upp lífþéttnistuðulinn 510 l/kg sem er undir gildinu 2000 l/kg sem gefur til kynna getuna til þess að safnast fyrir í lífverum.